KRAS Gene Mutation clinical trials at UC Cancer
1 research study open to eligible people
Experimental treatment combination, immunotherapy, (pembrolizumab), and targeted chemotherapy, (trametinib) for lung cancer
“Help us evaluate the effects of the combination of immunotherapy and targeted chemotherapy on non-small cell lung cancer”
open to eligible people ages 18 years and up
This phase Ib trial studies the side effects of pembrolizumab and trametinib in treating patients with non-small cell lung cancer and KRAS gene mutations that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and trametinib may work better in treating patients with non-small cell lung cancer.
at UC Davis